206 results
8-K
EX-99
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
11 Sep 06
Regulation FD Disclosure
12:00am
- EVP R&D, CHIEF SCIENTIFIC OFFICER
TOD MERTES
LIGAND PHARMACEUTICALS INCORPORATED - VP, CONTROLLER
WARNER BROADDUS LIGAND
PHARMACEUTICALS … are working to ensure that our R&D expense
going forward will be looked at carefully and will also be focused on specific
projects, which are most
8-K
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
18 Apr 11
Ligand Names Matthew W. Foehr Chief Operating Officer
12:00am
and development programs. Most recently he was Vice President and Head of Consumer Dermatology R&D, as well as Acting Chief Scientific Officer … of Dermatology, in the Stiefel division of GlaxoSmithKline (GSK). Following GSK’s $3.6 billion acquisition of Stiefel in 2009, Mr. Foehr led the R&D integration
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
18 Apr 11
Ligand Names Matthew W. Foehr Chief Operating Officer
12:00am
on Strategic Expansion of the CyDex Business and
Ligand’s R&D Operations
SAN DIEGO (April 18, 2011) – Ligand Pharmaceuticals Incorporated (NASDAQ … of experience managing global research and development programs. Most recently he was Vice President and Head of Consumer Dermatology R&D, as well
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
13 Oct 20
Entry into a Material Definitive Agreement
8:44am
is highly enthusiastic about securing a physical presence in the UK with a well-managed, fully built out R&D company. Ligand is focused on leveraging … a pleasure to work with as they solve important R&D challenges for partners,” continued Higgins.
Ligand retains economic rights to a portfolio of eight fully
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
4 Dec 12
Regulation FD Disclosure
12:00am
1) General Overview John Higgins Business Model Major Inflection Point Growth Drivers 2) Financial Overview and Outlook John Sharp 3) R&D Model … Projects Above-Average Growth, Below-Average Risk
8 Most programs fail in biotech/pharma R&D BUT, not all Ligand’s business model is premised
8-K
EX-99.1
h60b4s
18 Nov 14
Regulation FD Disclosure
12:00am
8-K
EX-99.1
mb8nn7r
9 Feb 11
Ligand Appoints John L. LaMattina to Board of Directors
12:00am
8-K
ydoulv443i4tcxwic6z
13 Oct 20
Entry into a Material Definitive Agreement
8:44am
8-K
EX-99.1
e2ipow89gk8glv
20 Oct 20
Results of Operations and Financial Condition
10:52am
8-K
EX-99.1
qwsmlc97ja gij
5 Mar 19
Entry into a Material Definitive Agreement
5:16pm
8-K/A
EX-99.1
hqle77 uh7uilrd
24 Jun 11
Regulation FD Disclosure
12:00am
CORRESP
zj7q z6ui
6 Jan 21
Correspondence with SEC
12:00am
8-K
EX-99.1
mhd 0fjdb
24 Sep 08
1 Joseph A. Mollica, Ph.D., Chairman of the Board, Interim President & CEO, Pharmacopeia John L. Higgins, President & CEO
12:00am
8-K
EX-99.1
mvqjv2s2
9 Feb 09
Regulation FD Disclosure
12:00am
8-K
317f5x1
3 Dec 20
Other Events
12:00am
8-K
EX-99.1
54clmcz7ipfeqqjtx5h
28 Jul 03
Financial statements and exhibits
12:00am
8-K
EX-99.1
22w2457yei1js2n0 dwp
6 Feb 07
Ligand Announces Corporate Restructuring
12:00am
8-K
EX-99.1
olghycd 0u9hfr4qlb
2 Feb 15
Departure of Directors or Certain Officers
12:00am
8-K
EX-99.1
a7xrdtbgc12jg74b
8 Oct 10
Ligand Appoints Sunil Patel to Board of Directors
12:00am
8-K
EX-99.3
ucinkswsb b3
31 Oct 06
Entry into a Material Definitive Agreement
12:00am